Medications for Follicular Lymphoma

11 results

  • breyanzi

    (Lisocabtagene Maraleucel)
    Juno Therapeutics, Inc.
    Breyanzi is a CD19-directed CAR-T cell immunotherapy for adults with relapsed or refractory large B-cell lymphoma, CLL/SLL, follicular lymphoma, mantle cell lymphoma, or marginal zone lymphoma after 2 or more prior lines of therapy. Not indicated for primary CNS lymphoma.
    Medication Details

  • brukinsa - zanubrutinib capsule

    (Zanubrutinib)
    Beone Medicines Usa, Inc.
    BRUKINSA is a kinase inhibitor for adults with mantle cell lymphoma, Waldenström's macroglobulinemia, chronic lymphocytic leukemia or small lymphocytic lymphoma, relapsed/refractory marginal zone lymphoma, and relapsed/refractory follicular lymphoma (with obinutuzumab).
    Medication Details
    Drug Interactions

  • epkinly - epcoritamab - bysp injection, solution

    (Epcoritamab-Bysp)
    Genmab Us, Inc.
    Epkinly treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma after 2+ prior therapies. Also indicated for relapsed or refractory follicular lymphoma (FL), with lenalidomide and rituximab or as monotherapy after 2+ prior therapies.
    Medication Details
    Drug Interactions

  • gazyva - obinutuzumab injection, solution, concentrate

    (Obinutuzumab)
    Genentech, Inc.
    GAZYVA treats previously untreated chronic lymphocytic leukemia (with chlorambucil), relapsed or refractory follicular lymphoma after rituximab-containing regimens (with bendamustine), previously untreated stage II bulky, III, or IV follicular lymphoma (with chemotherapy), and active lupus nephritis in adults on standard therapy.
    Medication Details
    Drug Interactions

  • kymriah

    (Tisagenlecleucel)
    Novartis Pharmaceuticals Corporation
    Kymriah is a CD19-directed CAR-T cell therapy for patients up to 25 with refractory or relapsed B-cell precursor ALL; adults with relapsed/refractory large B-cell lymphoma after 2+ prior therapies; and adults with relapsed/refractory follicular lymphoma after 2+ prior therapies (accelerated approval).
    Medication Details
    Drug Interactions

  • lunsumio - mosunetuzumab concentrate

    (Mosunetuzumab)
    Genentech, Inc.
    LUNSUMIO treats adult patients with relapsed or refractory follicular lymphoma after two or more prior lines of systemic therapy. Approved under accelerated approval based on response rate; continued approval may depend on confirmatory trial results.
    Medication Details
    Drug Interactions

  • revlimid - lenalidomide capsule

    (Lenalidomide)
    Celgene Corporation
    Revlimid treats adult patients with multiple myeloma (with dexamethasone or as maintenance after stem cell transplant), transfusion-dependent anemia from low-risk myelodysplastic syndromes with deletion 5q, relapsed mantle cell lymphoma, and previously treated follicular or marginal zone lymphoma (with rituximab).
    Medication Details
    Drug Interactions

  • rituxan hycela - rituximab and hyaluronidase injection, solution

    (Rituximab And Hyaluronidase)
    Genentech, Inc.
    Rituxan Hycela treats adult patients with follicular lymphoma (relapsed/refractory, previously untreated, or non-progressing after CVP), previously untreated diffuse large B-cell lymphoma with chemotherapy, and previously untreated or treated chronic lymphocytic leukemia with fludarabine and cyclophosphamide. Requires prior IV rituximab dose.
    Medication Details
    Drug Interactions

  • tazverik - tazemetostat tablet, film coated

    (Tazemetostat)
    Epizyme, Inc.
    Tazverik treats metastatic or locally advanced epithelioid sarcoma (adults and patients 16+) not eligible for resection, and relapsed/refractory follicular lymphoma in adults with EZH2 mutation or no satisfactory alternatives after 2+ prior therapies.
    Medication Details
    Drug Interactions

  • yescarta

    (Axicabtagene Ciloleucel)
    Kite Pharma, Inc.
    Yescarta is a CAR-T cell therapy for adults with large B-cell lymphoma refractory to or relapsing after first-line chemoimmunotherapy, or after two or more prior therapies. Also indicated for relapsed or refractory follicular lymphoma after two or more lines of systemic therapy (accelerated approval).
    Medication Details
    Drug Interactions